Table 1.
Baseline characteristics of patients in development and validation cohorts
| Frequency (%) | Development cohort (n = 302) | Validation cohort (n = 101) | p-value* |
|---|---|---|---|
| Median age | 67.0 years (range 39–83) | 69.0 years (range 39–84) | 0.179 |
| Gender (M:F) | 227 (75.2): 75 (24.8) | 78 (77.2): 23 (22.8) | 0.676 |
| Histology | 0.956 | ||
| Adenocarcinoma | 237 (78.5) | 79 (78.2) | |
| Squamous cell Carcinoma | 65 (21.5) | 22 (21.8) | |
| Tumour location | 0.003 | ||
| Oesophagus | 192 (63.6) | 47 (46.5) | |
| Upper third | 6 (3.1) | 3 (6.4) | |
| Middle third | 53 (27.6) | 10 (21.3) | |
| Lower third | 133 (69.3) | 34 (72.3) | |
| Junction | 110 (36.4) | 54 (53.5) | |
| Siewert I | 41 (37.3) | 24 (44.5) | |
| Siewert II | 30 (27.3) | 18 (33.3) | |
| Siewert III | 39 (35.4) | 12 (22.2) | |
| Stage groups | 0.238 | ||
| Stage 1 | 17 (5.6) | 2 (2.0) | |
| Stage 2 | 56 (18.5) | 24 (23.8) | |
| Stage 3 | 160 (53.1) | 57 (56.4) | |
| Stage 4 | 69 (22.8) | 18 (17.8) | |
| Treatment | 0.624 | ||
| Curative | 158 (52.3) | 50 (49.5) | |
| SA | 24 (15.2) | 4 (8.0) | |
| NACT | 67 (42.4) | 23 (46.0) | |
| NACRT | 13 (8.2) | 7 (14.0) | |
| dCRT | 54 (34.2) | 16 (32.0) | |
| Palliative | 144 (47.7) | 51 (50.5) | |
| Overall survival | <0.001 | ||
| Alive | 70 (23.2) | 43 (42.6) | |
| Dead | 232 (76.8) | 58 (57.4) |
SA surgery alone; NACT neo-adjuvant chemotherapy; NACRT neo-adjuvant chemoradiotherapy; dCRT definitive chemo-radiotherapy; *chi-square or Mann–Whitney U test